ADC Therapeutics S.A.
ADC Therapeutics S.A. is a clinical-stage oncology company developing antibody-drug conjugates, with a dominant political signal being $4.6M in concentrated insider buys by a single investment firm in early 2024.
BusinessWhat ADCT does
ADC Therapeutics S.A. is a clinical-stage biotechnology company focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its lead product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved for relapsed or refractory diffuse large B-cell lymphoma. The company's revenue is primarily derived from ZYNLONTA sales and collaboration agreements.
12 months past · 3 months futureADCT activity timeline
Lifetime Government AwardsADCT federal contracts
ADCT doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding ADCT
Politicians Trading ADCTMembers of Congress with recent ADCT positions
Congressional TradesWho in Congress is trading ADCT
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting ADCTLive legislation impacting this stock
Political ProfileWhere ADCT sits in Washington
[object Object]
STRUCTURAL: No federal contracts (get_government_precedent.federal_contracts_summary is null), $0 lobbying spend (get_political_influence.lobbying.total_income: 0), and no congressional trading (Top congressional traders array empty). EVIDENTIARY: A single investment firm, Redmile Group, executed 10 Form 4 purchases totaling ~$4.6M in Q1 2024 (Recent corp insider Form 4 buys). Net: Strong evidentiary cluster from a single non-executive entity is offset by a complete absence of structural political engagement.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
FDA regulatory review and post-marketing requirements for ZYNLONTA.U.S. Food and Drug Administration (FDA)"Inferred from primary industry (Pharmaceuticals) and sector (Healthcare); no direct bill impacts found in Recent bill_impacts array."
Regulatory opportunities
-
FDA approval for label expansions or new indications for pipeline ADCs.U.S. Food and Drug Administration (FDA)"Inferred from business description as a clinical-stage oncology company; no direct bill carveouts found in Recent bill_carveouts array."
Live signals + predictions for ADCT — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ADCT
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord